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M
edical research increasingly relies on collec-
tions of donated human tissue, such as
DNA samples, blood samples and solid
organs and tissues. These collections of
donated samples – referred to as biobanks,
biorepositories or tissue banks – can be used in basic science
experiments, population studies, or towards the refinement
and personalisation of medical and surgical techniques. 
The practice of collecting and systematically organising
biological samples is not new. Famous historical collections
were put together by Carl Linnaeus (1707–78) in Sweden,
Georges-Louis Leclerc, Comte de Buffon (1707–88) in France,
and Joseph Banks (1743–1820) in England. 
In recent years, however, advances in experimental tech-
niques (such as whole genome sequencing) and information
technologies (such as “big data” storage and analytics) have
massively increased the promise of biomedical research using
collections of human biological samples. 
In order for the promise of biobanks to be fulfilled, large
numbers of samples need to be collected, stored and analysed.
Until recently, most biobanks were located within individual
universities, research institutes or health facilities, and often
tied to specific research projects. 
Increasingly, however, biobanks have become “networked”
in an effort to become more sustainable and to increase their
utility. Most often, these networks of biobanks draw together
samples from within a country to create a single biobank that
may be accessible to researchers based in different institutions
and with different research interests. 
But even large domestic biobanks or biobank networks like
these may still lack the statistical power to answer important
research questions. For example, research into the genetics of
rare or complex diseases often requires the analysis of samples
that number in the hundreds of thousands, if not millions.
Maximising the full potential of biobanks is therefore difficult
within the confines of a single nation.
As a result, biobanks are now “going global”. This can happen
in a number of ways. One possible model is that a single biobank
might collect biological samples from numerous countries.
Several biobanks in the United States, for instance, use a “direct-
to-consumer” model in which they sell genetic testing to
customers in numerous countries, and in the process build their
biorepositories. 
An alternative model is to form virtual networks across
national borders through the use of data-sharing technologies
and the latest bioinformatic platforms. For example, biobanks
in the European Union and the Community of Latin Amer-
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Global networks of depositories for biological samples
open a range of scientiﬁc, legal and ethical challenges. 
Once a biobank shares samples or
biodata with another institution,
how can they control or oversee the
uses, or on-selling, of that tissue?
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ican and Caribbean States have established extensive data-
sharing networks that have proven to be useful biodata repos-
itories for tissue samples that are spread across multiple countries. 
A third model is for a biobank to distribute its operations,
in a compartmentalised way, across numerous countries. For
example, a biobank might collect data samples in one country,
store these samples in another country and conduct data anal-
ysis in yet another location. 
While there is enormous excitement about these large
biobank networks, the reality is that “going global” is not
straightforward. Broadly speaking, barriers to the globalisation
of biobanking can be divided into technical issues, ethical issues
and economic issues. 
Technical issues relate to the sheer size and scale of the
bionetworks that are being created, and include challenges asso-
ciated with collecting, storing, linking and analysing large
amounts of data. Participants may need to be recruited at
numerous locations to donate samples, undergo a baseline
survey and then be followed-up at a later date. 
Biobank networks may struggle to ensure that standard scien-
tific practices have been used in every location. Scientific practices,
though ostensibly objective and standardised, do not actually
exhibit the universal consistency that one might imagine. Whether
it’s the concentration of reagents, the temperature of storage or
the basic equipment used in the laboratory, the technical side of
collecting samples for storage can be highly variable. 
From an ethical perspective, those who want to establish
global biobanks have to carefully navigate a whole range of
issues including informed consent, confidentiality, control of
data access, right to withdraw, accessibility to biospecimens,
ownership, benefit sharing, commercialisation, intellectual
property rights, genetic discrimination, community engage-
ment, respect for tissue, cultural diversity, beneficence,
reciprocity and equity. 
Consent refers to informing tissue donors about the research,
its associated risks and benefits, and obtaining permission from
them to use their tissue. Consent can be narrow for specific
research projects or broad, covering a wide range of present
and future projects. 
Confidentiality refers to the need to protect the anonymity
of the donors who have donated samples. Information associ-
ated with or derived from a sample may reveal deep insights
into individuals’ personal lives, and thus privacy is a key issue. 
Ownership of tissue also needs to be negotiated carefully,
not just between donors and the biobank but also between
biobanks and the researchers studying and analysing the samples. 
A concern for benefit sharing means that the distribution of
benefits from the findings of biobank research are equitably
shared within and across populations, with due consideration
to the donors who provided the samples. 
Respect for the samples means using and disposing of tissues
in accordance with the values, beliefs and preferences of the
donor. Observing these ethical principles locally is an impor-
tant part of establishing and maintaining trust between a
biobank and the general public.
“Going global” not only magnifies existing ethical issues
associated with collecting human biological samples, but also
opens up a range of new ethical considerations. A key issue that
arises as biobanks globalise is the custodianship of tissue. Once
a biobank shares samples or biodata with another institution,
how can they control or oversee the uses, or on-selling, of that
tissue? This matters because the networking of samples opens
the space for uses by unknown and possibly unregulated groups
whose projects may not be covered by the original research
ethics approval and donor consent. The transfer of samples
across national boundaries also creates challenges to do with
access to samples. 
The right to withdraw from research participation without
any consequences is standard practice in contemporary bio -
medical research. This raises the question of what, if any, recourse
do donors have to ensure the destruction of their sample if it
has been transported abroad? 
Even more ethical issues are raised when inequalities between
low-income and high-income countries are considered. Coun-
tries already dominant in the field are currently setting the
research agenda and financial feasibility of global biobanks. If
donor tissue is exported from the developing world to the devel-
oped world, could people in low-income populations be
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exploited? Additionally, how can researchers ensure that bene-
fits are shared across national boundaries? 
Advances in IT platforms will undoubtedly go some way to
addressing the ethical and practical challenges associated with
biobank networks. Work done at Oxford University as part
of the EnCoRe (Ensuring Consent and Revocation) Project
(http://tinyurl.com/jlhpb6x), for example, has raised the possi-
bility of more dynamic models of consent and communication
that would enable donors to direct, with much greater precision
and nuance, what projects they would consent to their sample
and data being used in and what they, in return, would like to
receive from this research and from their biobank. 
While this model of dynamic consent offers considerable
promise, and has already been adopted around the globe, it
requires enormous capital investment and massive technolog-
ical sophistication and may, at least initially, deepen the digital
divide between rich and poor. Just as importantly, such advances
in IT capacity leave unanswered the more fundamental ques-
tions regarding the purpose of research involving biobanks and
the sharing or dissemination of the economic and health bene-
fits that may flow from them.
Economic challenges associated with the global networking
of biobanks stem from the fact that the infrastructure and
human expertise required to maintain biobanks is incredibly
costly, which puts a lot of pressure on traditional not-for-profit
organisational and research funding models. Commercial
funding is an obvious alternative, but while the commerciali-
sation of a biobank can be a boon to the translation of basic
research to clinical application, it is a sensitive matter with
regards to ownership, property rights and benefit sharing. 
All of these technical, ethical and economic issues are further
complicated by differing regulatory and ethical standards in
different settings. These differences raise questions about what
regulatory and ethical issues come into play when tissue is
collected in one country and stored in another, and whether a
biobank must respond to the regulatory and ethical standards
and practices of the home country of the donor or the national
location of the biobank. 
International organisations such as the International Society
for Biological and Environmental Repositories (ISBER), the
United Nations Educational, Scientific and Cultural Organi-
sation (UNESCO) and the Organisation for Economic Coop-
eration and Development (OECD) have put together guidelines
that attempt to address the technical, legal, ethical and manage-
rial issues relevant to collecting, storing, retrieving and
distributing samples from human bodies for diagnostic, ther-
apeutic, educational, forensic and research purposes. Currently,
however, the operations of biobanks still operate according to
national governance frameworks. 
This will need to change if global networking of biobanks are
to achieve their scientific promise. The competing demands of
donors, investors, researchers, medical practitioners, patients,
families and others who might benefit from tissue collections
must be balanced so that the research priorities of biobanks
address the heterogeneous needs of diverse human populations
in meaningful and ethical ways. 
Global biobanks are set to provide revolutionary insights
into the causes of morbidity and mortality, and lead to substan-
tial transformations in the delivery of personalised medicine.
However, the potential benefits of “going global” will be under-
mined if technical, ethical and economic considerations are
not systematically considered and resolved.
Paul H. Mason, Wendy Lipworth and Ian Kerridge research the ethics of global biobanks at
the Centre for Values, Ethics and the Law in Medicine at The University of Sydney.
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The competing demands of donors,
investors, researchers, medical
practitioners, patients, families and
others who might beneﬁt from
tissue collections must be balanced
so that the research priorities of
biobanks address the
heterogeneous needs of diverse
human populations...
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